Summit Therapeutics pleased with new BARDA partnership investment

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) Investor Relations Senior Director Michelle Avery sat down with Proactive's Christine Corrado at BIO CEO in New York. The company recently announced The Biomedical Advanced Research and Development Authority (BARDA) is investing a further $8.8mln into the advancement of Summit’s precision drug ridinilazole for the treatment of C. difficile infection (CDI), taking the total value of the award to $72.5mln.